Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials.
暂无分享,去创建一个
H. Schunkert | M. Joner | A. Kastrati | T. Tada | K. Laugwitz | R. Byrne | S. Cassese | P. Hoppmann | M. Fusaro
[1] I. Porto,et al. Meta‐analysis of bioabsorbable versus durable polymer drug‐eluting stents in 20,005 patients with coronary artery disease: An update , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] G. Stone,et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. , 2014, Journal of the American College of Cardiology.
[3] Shuyang Zhang,et al. Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus Durable Polymer Drug-Eluting Stents: A Meta-Analysis , 2013, PloS one.
[4] Mario Fusaro,et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis , 2013, BMJ.
[5] H. Suryapranata,et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis , 2013, BMJ.
[6] P. Serruys,et al. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. , 2013, International journal of cardiology.
[7] F. Eberli,et al. Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi , 2022 .
[8] T. Akasaka,et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. , 2013, Journal of the American College of Cardiology.
[9] C. Terkelsen,et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.
[10] M. Togni,et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial , 2013, The Lancet.
[11] D. Holmes,et al. Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.
[12] A. Kastrati,et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. , 2012, European heart journal.
[13] Yuji Ikari,et al. Randomized comparison of the nobori biolimus A9‐eluting stent with the sirolimus‐eluting stent in patients with stenosis in native coronary arteries , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] Deepak L. Bhatt,et al. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[15] W. Wijns,et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[17] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.
[18] S. King,et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. , 2012, JACC. Cardiovascular interventions.
[19] F. Eberli,et al. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. , 2012, American heart journal.
[20] F. Eberli,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.
[21] W. Wijns,et al. Nobori™ drug eluting stent system: clinical evidence update. , 2010, Minerva cardioangiologica.
[22] P. Serruys,et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. , 2010, European heart journal.
[23] M. Joner,et al. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.
[24] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[25] E. Hannan,et al. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies , 2009, Circulation.
[26] P. Serruys,et al. Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2 , 2009, Circulation. Cardiovascular interventions.
[27] C. von Birgelen,et al. Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[28] A. Kastrati,et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. , 2009, JACC. Cardiovascular interventions.
[29] R. Virmani,et al. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing? , 2009, JACC. Cardiovascular interventions.
[30] U. Christians,et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK study , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[31] W. Wijns,et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.
[32] Michael Joner,et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.
[33] P. Serruys,et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[34] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[35] J. Hilborn,et al. Effects of hydrolysis on a new biodegradable co-polymer , 2006, Journal of biomaterials science. Polymer edition.
[36] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[37] Jonathan A C Sterne,et al. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.
[38] M. Egger,et al. The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.